Female Health ROA 2006-2018 | VERU
Current and historical return on assets (ROA) values for Female Health (VERU) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Female Health ROA for the three months ending December 31, 2018 was -41.10%.
| Female Health ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2018-12-31 | $-0.02B | $0.05B | -41.71% |
| 2018-09-30 | $-0.02B | $0.05B | -45.71% |
| 2018-06-30 | $-0.02B | $0.05B | -38.71% |
| 2018-03-31 | $-0.01B | $0.06B | -25.34% |
| 2017-12-31 | $-0.01B | $0.05B | -21.82% |
| 2017-09-30 | $-0.01B | $0.06B | -15.65% |
| 2017-06-30 | $-0.01B | $0.06B | -11.21% |
| 2017-03-31 | $-0.00B | $0.06B | -8.08% |
| 2016-12-31 | $-0.00B | $0.06B | -4.42% |
| 2016-09-30 | $0.00B | $0.04B | 0.00% |
| 2016-06-30 | $0.00B | $0.04B | 7.64% |
| 2016-03-31 | $0.00B | $0.04B | 7.84% |
| 2015-12-31 | $0.01B | $0.04B | 13.42% |
| 2015-09-30 | $0.01B | $0.04B | 13.99% |
| 2015-06-30 | $0.00B | $0.04B | 8.70% |
| 2015-03-31 | $0.00B | $0.04B | 8.96% |
| 2014-12-31 | $0.00B | $0.03B | 3.05% |
| 2014-09-30 | $0.00B | $0.03B | 3.01% |
| 2014-06-30 | $0.01B | $0.03B | 26.47% |
| 2014-03-31 | $0.01B | $0.03B | 26.67% |
| 2013-12-31 | $0.01B | $0.04B | 35.56% |
| 2013-09-30 | $0.02B | $0.04B | 46.15% |
| 2013-06-30 | $0.02B | $0.03B | 51.20% |
| 2013-03-31 | $0.02B | $0.03B | 61.02% |
| 2012-12-31 | $0.02B | $0.03B | 62.96% |
| 2012-09-30 | $0.02B | $0.03B | 64.65% |
| 2012-06-30 | $0.01B | $0.03B | 59.09% |
| 2012-03-31 | $0.01B | $0.02B | 51.28% |
| 2011-12-31 | $0.01B | $0.02B | 45.07% |
| 2011-09-30 | $0.01B | $0.02B | 29.85% |
| 2011-06-30 | $0.01B | $0.02B | 36.36% |
| 2011-03-31 | $0.01B | $0.02B | 36.92% |
| 2010-12-31 | $0.01B | $0.02B | 49.23% |
| 2010-09-30 | $0.01B | $0.02B | 44.44% |
| 2010-06-30 | $0.00B | $0.01B | 18.75% |
| 2010-03-31 | $0.00B | $0.02B | 24.62% |
| 2009-12-31 | $0.00B | $0.02B | 25.81% |
| 2009-09-30 | $0.01B | $0.02B | 47.46% |
| 2009-06-30 | $0.01B | $0.02B | 51.85% |
| 2009-03-31 | $0.01B | $0.01B | 53.85% |
| 2008-12-31 | $0.01B | $0.01B | 46.15% |
| 2008-09-30 | $0.01B | $0.01B | 37.74% |
| 2008-06-30 | $0.00B | $0.01B | 32.00% |
| 2008-03-31 | $0.00B | $0.01B | 26.09% |
| 2007-12-31 | $0.00B | $0.01B | 19.05% |
| 2007-09-30 | $0.00B | $0.01B | 10.81% |
| 2007-06-30 | $0.00B | $0.01B | 0.00% |
| 2007-03-31 | $0.00B | $0.01B | 0.00% |
| 2006-12-31 | $0.00B | $0.01B | 0.00% |
| 2006-09-30 | $0.00B | $0.01B | 0.00% |
| 2006-06-30 | $0.00B | $0.01B | 0.00% |
| 2006-03-31 | $0.00B | $0.01B | 0.00% |
| 2005-12-31 | $0.00B | $0.01B | 0.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.084B | $0.016B |
| Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered in Miami, FL. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $132.673B | 26.23 |
| Medtronic (MDT) | Ireland | $124.635B | 18.20 |
| Stryker (SYK) | United States | $69.927B | 25.67 |
| Boston Scientific (BSX) | United States | $55.591B | 27.10 |
| Baxter (BAX) | United States | $39.448B | 24.31 |
| Zimmer Biomet Holdings (ZBH) | United States | $25.289B | 16.23 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.755B | 0.00 |
| ResMed (RMD) | United States | $14.297B | 27.11 |
| Canopy Growth (CGC) | Canada | $10.742B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $8.172B | 52.25 |
| Aurora Cannabis (ACB) | Canada | $7.060B | 50.50 |
| Hill-Rom Holdings (HRC) | United States | $6.958B | 21.52 |
| Perrigo (PRGO) | Ireland | $6.649B | 10.09 |
| ICU Medical (ICUI) | United States | $5.184B | 28.88 |
| Insulet (PODD) | United States | $5.071B | 0.00 |
| Haemonetics (HAE) | United States | $4.540B | 40.28 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $4.400B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $3.380B | 0.00 |
| Hutchison China MediTech (HCM) | China | $3.329B | 0.00 |
| Neogen (NEOG) | United States | $3.267B | 50.18 |
| NuVasive (NUVA) | United States | $2.850B | 24.96 |
| Quidel (QDEL) | United States | $2.761B | 24.91 |
| National Vision Holdings (EYE) | United States | $2.637B | 51.01 |
| Aphria (APHA) | $2.539B | 112.78 | |
| NxStage Medical (NXTM) | United States | $2.000B | 0.00 |
| AtriCure (ATRC) | United States | $1.274B | 0.00 |
| HEXO (HEXO) | $1.242B | 0.00 | |
| Cardiovascular Systems (CSII) | United States | $1.240B | 890.25 |
| Phibro Animal Health (PAHC) | United States | $1.220B | 17.53 |
| VAREX IMAGING (VREX) | United States | $1.212B | 23.73 |
| MacroGenics (MGNX) | United States | $0.939B | 0.00 |
| Cerus (CERS) | United States | $0.904B | 0.00 |
| PetIQ (PETQ) | United States | $0.867B | 22.47 |
| Lantheus Holdings (LNTH) | United States | $0.847B | 22.95 |
| Surmodics (SRDX) | United States | $0.785B | 114.20 |
| Meridian Bioscience (VIVO) | United States | $0.733B | 21.85 |
| NanoString Technologies (NSTG) | United States | $0.721B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.720B | 31.76 |
| Omeros (OMER) | United States | $0.719B | 0.00 |
| Evolus (EOLS) | United States | $0.705B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.647B | 20.75 |
| LeMaitre Vascular (LMAT) | United States | $0.603B | 28.76 |
| Quanterix (QTRX) | United States | $0.518B | 0.00 |
| Insys Therapeutics (INSY) | United States | $0.426B | 0.00 |
| Owens & Minor (OMI) | United States | $0.408B | 5.65 |
| TG Therapeutics (TGTX) | United States | $0.398B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.339B | 21.99 |
| BioLife Solutions (BLFS) | United States | $0.329B | 445.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.294B | 0.00 |
| Vapotherm (VAPO) | United States | $0.288B | 0.00 |
| Bovie Medical (APYX) | United States | $0.282B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.262B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.256B | 0.00 |
| Zynex (ZYXI) | United States | $0.174B | 16.84 |
| Fonar (FONR) | United States | $0.144B | 7.70 |
| Surface Oncology (SURF) | United States | $0.140B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.112B | 0.00 |
| Chimerix (CMRX) | United States | $0.100B | 0.00 |
| United-Guardian (UG) | United States | $0.090B | 18.77 |
| InfuSystems Holdings (INFU) | United States | $0.078B | 0.00 |
| CAS Medical Systems (CASM) | United States | $0.070B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.066B | 18.20 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.057B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.056B | 0.00 |
| ImmuCell (ICCC) | United States | $0.038B | 0.00 |
| Neurotrope (NTRP) | United States | $0.034B | 0.00 |
| Senestech (SNES) | United States | $0.021B | 0.00 |
| Myomo (MYO) | United States | $0.016B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.014B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.014B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.013B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.010B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 14.14 |
